The primary efficacy outcome occurred in @/@ ( @ % ) and @/@ ( @ % ) patients in the edoxaban and enoxaparin groups , respectively ( relative risk reduction = @ % ) , indicating non-inferiority ( P < @ ) and superiority ( P = @ ) of edoxaban versus enoxaparin .